NCT03998254View on ClinicalTrials.gov

Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

6,000

Participants

Timeline

Start Date

June 26, 2019

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Papillomavirus Infections
Interventions
DRUG

V503

9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine

DRUG

Gardasil

qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine

Trial Locations (6)

541200

Lingchuan Center for Disease Control and Prevention ( Site 0002), Guilin

541500

Quanzhou Center for Disease Control and Prevention ( Site 0001), Guilin

621000

Mianyang Center for Disease Control and Prevention ( Site 0005), Mianyang

621100

Santai County Center for Disease Control and Prevention ( Site 0006), Mianyang

046299

Xiangyuan Center for Disease Control and Prevention ( Site 0003), Changzhi

044000

Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0004), Yuncheng

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03998254 - Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | Biotech Hunter | Biotech Hunter